{"DataElement":{"publicId":"2718476","version":"1","preferredName":"Neoadjuvant Treatment Administered Type","preferredDefinition":"the type of neoadjuvant treatment administered.","longName":"NEOADJ_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2188393","version":"1","preferredName":"Neoadjuvant Therapy Administered","preferredDefinition":"information related to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents, being administered.","longName":"NEOADJ_TX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2718486","version":"1","preferredName":"Neoadjuvant Therapy","preferredDefinition":"Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.","longName":"C15665","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D7D4EB-6EB9-0FF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"ONEDATA","dateModified":"2008-01-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E40DA276-BE0A-601E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-28","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-09-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2718477","version":"1","preferredName":"Neoadjuvant Therapy Type","preferredDefinition":"the type of neoadjuvant therapy.","longName":"NEOADJTX_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Radiation Therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2717922","version":"1","preferredName":"Radiation Therapy","longName":"2717922","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42BFA254-C33F-032A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42D79B0B-2162-74F3-E044-0003BA3F9857","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"CAMPBELB","dateModified":"2008-01-03","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42D79B0B-216E-74F3-E044-0003BA3F9857","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"CAMPBELB","dateModified":"2008-01-03","deletedIndicator":"No"},{"value":"Capecitabine","valueDescription":"Capecitabine","ValueMeaning":{"publicId":"2718478","version":"1","preferredName":"Capecitabine","longName":"2718478","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D79B0B-217A-74F3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42D79B0B-2193-74F3-E044-0003BA3F9857","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"CAMPBELB","dateModified":"2008-01-03","deletedIndicator":"No"},{"value":"Infusional 5FU","valueDescription":"Infusional Fluorouracil","ValueMeaning":{"publicId":"2718479","version":"1","preferredName":"Infusional Fluorouracil","longName":"2718479","preferredDefinition":"A method of putting Fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity, into the bloodstream.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D7AEF4-A4E4-6AF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42D87D68-40CB-698D-E044-0003BA3F9857","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"ONEDATA","dateModified":"2008-01-03","deletedIndicator":"No"},{"value":"Bolus 5FU","valueDescription":"Bolus Fluorouracil","ValueMeaning":{"publicId":"2718480","version":"1","preferredName":"Bolus Fluorouracil","longName":"2718480","preferredDefinition":"A single dose of Fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity, usually injected into a blood vessel over a short period of time.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D81E67-6194-514C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"42D87D68-40DD-698D-E044-0003BA3F9857","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"ONEDATA","dateModified":"2008-01-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D79B04-5C0D-7232-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Therapy received","type":"Preferred Question Text","description":"Therapy received","url":null,"context":"CTEP"}],"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"42D87D68-409B-698D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}